AR111409A1 - Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos de antraciclinas - Google Patents

Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos de antraciclinas

Info

Publication number
AR111409A1
AR111409A1 ARP180100849A ARP180100849A AR111409A1 AR 111409 A1 AR111409 A1 AR 111409A1 AR P180100849 A ARP180100849 A AR P180100849A AR P180100849 A ARP180100849 A AR P180100849A AR 111409 A1 AR111409 A1 AR 111409A1
Authority
AR
Argentina
Prior art keywords
splice variant
nucleic acid
chemotherapeutic agents
gene
oligonucleotides
Prior art date
Application number
ARP180100849A
Other languages
English (en)
Spanish (es)
Inventor
Shikha Saini
Fei Yue
Aditi Mathur
Sidney Hopps
Bellur Prabhakar
Original Assignee
Jivana Biotechnology Inc
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jivana Biotechnology Inc, Univ Illinois filed Critical Jivana Biotechnology Inc
Publication of AR111409A1 publication Critical patent/AR111409A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP180100849A 2017-04-24 2018-04-05 Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos de antraciclinas AR111409A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762489056P 2017-04-24 2017-04-24

Publications (1)

Publication Number Publication Date
AR111409A1 true AR111409A1 (es) 2019-07-10

Family

ID=63919814

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180100849A AR111409A1 (es) 2017-04-24 2018-04-05 Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos de antraciclinas

Country Status (3)

Country Link
AR (1) AR111409A1 (fr)
TW (1) TW201902912A (fr)
WO (1) WO2018200144A2 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084954A2 (fr) * 2006-01-19 2007-07-26 The Board Of Trustees Of The University Of Illinois Inhibition sélective des variantes d'épissure de l'ig20 pour traiter le cancer

Also Published As

Publication number Publication date
TW201902912A (zh) 2019-01-16
WO2018200144A3 (fr) 2018-11-29
WO2018200144A2 (fr) 2018-11-01

Similar Documents

Publication Publication Date Title
MX2018013157A (es) Analogos de oligonucleotidos dirigidos a lmna humana.
CL2018000818A1 (es) Composición de oligonucleotidos; métodos para alterar el empalme de un transcripto blanco; y uso de la composición para tratar distrofia muscular de duchenne.
CL2017001956A1 (es) Oligomeros antisentido de tau y uso de los mismos
BR122021025194A8 (pt) Molécula de ácido nucleico, método para obter rna, rna, método para obter um peptídeo ou proteína e usos in vitro ou ex vivo do rna
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
WO2013086444A3 (fr) Procédés pour traiter des laminopathies progéroïdes utilisant des analogues d'oligonucléotide ciblant lmna humain
PE20171763A1 (es) Composiciones y metodos para inhibir la expresion del gen hao1 (hidroxiacido-oxidasa 1 (glicolato-oxidasa))
AR090641A1 (es) Composiciones y metodos para inhibir la expresion del gen alas1
AR091539A1 (es) INHIBIDORES DE LA FAMILIA miR-15 DE MICRO-ARN
PE20181448A1 (es) Composiciones y metodos para disminuir la expresion de tau
CL2020002563A1 (es) Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b
CL2021001552A1 (es) Moléculas inhibidoras de ácido nucleico de doble hebra que contienen un triloop
EA201791986A1 (ru) Олигонуклеотиды, соответствующие экзону 73 гена col7a1, для терапии буллезного эпидермолиза
BR112017018329A2 (pt) composição para prevenir ou tratar calcificação de válvula, contendo inibidor de dpp-4
MX2019003070A (es) Terapia de combinacion con oligonucleotidos antisentido liposomales.
CL2021002842A1 (es) Moléculas inhibidoras de ácido nucleico bicatenario con cadenas de sentido acortadas
MX2022009870A (es) Ácidos ribonucleicos (arn) para la inhibición del complemento.
AR120341A1 (es) COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
AR111409A1 (es) Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos de antraciclinas
MX2017014855A (es) Oligonucleotidos atisentido para tratar epidermolisis bullosa distrofica.
AR111587A1 (es) Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos alquilantes
AR111410A1 (es) Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos inhibidores de proteína quinasas
WO2016107933A3 (fr) Matériaux et méthodes pour le traitement de cancers
CO2020010226A2 (es) Terapia con oligonucleotidos para la enfermedad de wilson
AR111449A1 (es) Combinación sinérgica de oligonucleótidos de ácidos nucleicos y quimioterapia con taxanos

Legal Events

Date Code Title Description
FB Suspension of granting procedure